Literature DB >> 29128074

Flow Cytometry in Pediatric Hematopoietic Malignancies.

Jie Li1, Gerald Wertheim1, Michele Paessler2, Vinodh Pillai3.   

Abstract

Utility of flow cytometry in the evaluation of pediatric hematopoietic neoplasms and the differences from adult hematopoietic neoplasms are discussed in this review. Distinction of hematogones from B-lymphoblasts, detection of residual/relapsed disease after novel targeted therapies, and evaluation of pediatric myeloid neoplasms are discussed.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hematogones; Leukemia; Lymphoblasts; Lymphoma; Pediatric flow cytometry

Mesh：

Year:  2017        PMID： 29128074     DOI： 10.1016/j.cll.2017.07.009

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  2 in total

1.  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Authors:  Vinodh Pillai; Kavitha Muralidharan; Wenzhao Meng; Asen Bagashev; Derek A Oldridge; Jaclyn Rosenthal; John Van Arnam; Jos J Melenhorst; Diwakar Mohan; Amanda M DiNofia; Minjie Luo; Sindhu Cherian; Jonathan R Fromm; Gerald Wertheim; Andrei Thomas-Tikhonenko; Michele Paessler; Carl H June; Eline T Luning Prak; Vijay G Bhoj; Stephan A Grupp; Shannon L Maude; Susan R Rheingold
Journal:  Blood Adv       Date:  2019-11-26

2.  An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters.

Authors:  Neha Bhagwat; Keely Dulmage; Charles H Pletcher; Ling Wang; William DeMuth; Moen Sen; David Balli; Stephanie S Yee; Silin Sa; Frances Tong; Liping Yu; Jonni S Moore; Ben Z Stanger; Eric P Dixon; Erica L Carpenter
Journal:  Sci Rep       Date:  2018-03-22       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.